On Growth Option for R&D Continuity of BiotechStart-up under Uncertainty
On Growth Option for R&D Continuity of BiotechStart-up under Uncertainty
复制标题
关于 R 的增长选项
DOI：
10.1007/s40171-012-0013-6
复制
发表时间：
2012
影响因子：
--
通讯作者：
Takao
中科院分区：
文献类型：
--
作者：
FUJIWARA;Takao
For biotech drug-discovery start-ups, even though the constraint on managerial resources is very severe, it takes more than 10 years for them to transfer a project from laboratory study to products on the market. In order to increase robustness against financial crisis for continuing R&D, we examine the flexibility value of real options, and especially pay attention to the function of growth options for business entry and exit. Through a case study of a Japanese pioneering start-up in the field of regenerative medicine, J-TEC, we consider a survival strategy during the valley of deficit from the perspective of the growth option. Finally, we apply stochastic optimization to select the pipeline candidates from alternative projects.
